Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8116419 | 0.80 | KEAP1 (0.36) | — | |
| SCHEMBL622920 | 0.78 | DDB1 (0.34) | — | |
| SCHEMBL16956643 | 0.78 | — | — | |
| SCHEMBL900817 | 0.78 | EPHX2 (0.32) | — | |
| SCHEMBL17046259 | 0.77 | CA2 (0.33) | — | |
| SCHEMBL1064604 | 0.77 | CA1 (0.38) | — | |
| SCHEMBL16953264 | 0.76 | MEN1 (0.35) | — | |
| SCHEMBL592798 | 0.76 | GRIA1 (0.31) | — | |
| SCHEMBL1068440 | 0.76 | HSD11B1 (0.33) | — | |
| SCHEMBL458982 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | claimed |
| EP-3157922-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2018-11-28 | — | — | EP | claimed |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | claimed |
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-07-19 | — | — | US | claimed |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BY) | 2018-06-19 | — | — | US | claimed |
| US-9969748-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-05-15 | — | — | US | claimed |
| EP-2935269-B1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2018-04-11 | — | — | EP | claimed |
| US-9714248-B2 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2017-07-25 | — | — | US | claimed |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | claimed |
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-05-04 | — | — | US | claimed |
| US-20170121324-A1 | Pyrazolo-Pyridine Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2017-05-04 | — | — | US | claimed |
| EP-3157922-A1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2017-04-26 | — | — | EP | claimed |
| EP-3157924-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2017-04-26 | — | — | EP | claimed |
| EP-3157923-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2017-04-26 | — | — | EP | claimed |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2016-07-07 | — | — | US | claimed |
| WO-2015193167-A1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | claimed |
| WO-2015193169-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | claimed |
| WO-2015193168-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | claimed |
| EP-2935269-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2015-10-28 | — | — | EP | claimed |
| WO-2014096423-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2014-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | SCN8A 4287/4885 |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | HAVCR2, TPMT, NFATC1 | SCN8A 3623/4885 |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2A | SCN8A 3601/4885 |
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | SCN8A 4254/4885 |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | SCN8A 4287/4885 |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | PI4KB, PI4KA, PI4K2B | SCN8A 4254/4885 |
| US-20170121324-A1 | Pyrazolo-Pyridine Derivatives as Kinase Inhibitors | PI4KA, PI4KB, PI4K2A | SCN8A 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.